It is highly deplorable to overreact, entice fear and spread misinformation without doing any due diligence on COVID-19 vaccine, Union Health Minister Harsh Vardhan said on Tuesday after Bharat Biotech released a factsheet specifying conditions when Covaxin should not be given.
He was replying to a tweet that asked why such a crucial information was allegedly not made public earlier.
The health minister also referred to an earlier tweet by him on January 15, wherein he had posted a chart with details of all those people who should not get the vaccine.
"Highly deplorable to over-react, entice fear and spread misinformation without performing an iota of due diligence. These facts have been in public domain since the beginning. Follow @MoHFW_INDIA (health ministry Twitter handel) to stay informed and do some research before speaking out," Vardhan tweeted.
In the factsheet on COVID-19 vaccine Covaxin, Bharat Biotech has advised pregnant or breastfeeding women and people with high fever or bleeding disorders not to take the antidote.
The vaccine maker in the fact sheet on Covaxin, posted in its website, said the clinical efficacy of the vaccine is yet to be established and is being studied in phase three clinical trial, and hence it is important to appreciate that receiving the vaccine does not mean other precautions related to COVID-19 need not be followed.
Covaxin has been granted approval for restricted use in emergency situations.
It is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)